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Abstract: Hotspot codon 132 mutations (R132xIDH1m) are frequent in intrahepatic
cholangiocarcinoma (ICC), are druggable by anti-IDH1m agents, and could represent a marker of
disease progression. Developing an assay to identify R132xIDH1m would provide a useful tool to
select patients benefitting from targeted treatments. We tested a quantitative real-time allele-specific
polymerase chain reaction (qPCR)-based method to detect the main R132xIDH1m in an Italian
ICC series (n = 61) of formalin-fixed paraffin-embedded (FFPE) samples, and on circulating-free
DNA samples. The outcomes were compared with nested PCR/Sanger sequencing. Reconstitution
experiments of plasmids harboring the different R132xIDH1m mixed with wild-type (WT) DNA
demonstrated that qPCR is able to detect at least 2% of all mutated allele. High efficiency was also
observed on patient-derived mutated DNA mixed with WT DNA (up to 10% and 0.3 ng of mutated
template); qPCR detected 16.4% of mutated samples (one R132G, three R132C and six R132L) while
nested PCR/Sanger sequencing only 8.2% (four R132L and one R132G). In a single patient with an
R132C-mutated tumor, qPCR was also performed on plasma samples collected at four time-points,
observing an increase correlating with disease progression. In conclusion, we developed a qPCR
assay which could represent a fast, inexpensive and sensitive tool both for detection of R132xIDH1m
in ICC samples and monitoring disease progression from liquid biopsy.
Keywords: IDH1 mutation; intrahepatic cholangiocarcinoma; qPCR; liquid biopsy; biomarker
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1. Introduction
Intrahepatic cholangiocarcinoma (ICC) is a malignancy arising from the epithelial cells of the
intrahepatic bile duct branches of the second-order or beyond. The incidence of ICC accounts for
10–20% of all cholangiocarcinomas (CCA) and 3% of gastrointestinal carcinomas [1,2]. The etiological
spectrum varies with the geographical region [3]. The median survival time in ICC patients is
as low as 2–6 months if only palliative treatment is administered. The 5 year survival rate after
surgical resection still lies around 30–35% [4]. Although surgery is the main treatment option for early
ICC, only approximately one-third of ICC patients undergo surgical resection. Survival time in the
advanced setting exceeds 5 years in less than 10% of patients, regardless of the systemic treatment
employed [5]. Since chemotherapy approaches have provided poor benefits in terms of survival,
deep molecular studies have been conducted in the last years, with the aim of identifying molecular
drivers as well as potential targets for tailored therapies. In particular, the mutational status of the
main ICC cancer related genes was analyzed in different cohorts of patients. Globally, among the
most frequently mutated genes, literature data reported KRAS, BRAF, TP53, ARID1A, MLL3, ROBO2,
RNF43, PEG3, GNAS, IDH1/2, BAP1, FGFR and ROS fusions [6–11], suggesting potential targets for
therapy. Diverse factors, encompassing ethnicity, risk factors and hepatic localization could influence
the mutational spectrum of ICC. In fact, Ong and collaborators analyzed a cohort of liver fluke
cholangiocarcinomas, evidencing a different mutational landscape than in non-liver fluke infected
patients [8]. The incidence in BRAF and KRAS mutations is higher in Asian than European countries.
In a recent study by Farshidfar and collaborators, a deep molecular investigation was performed on
38 CCA samples, mainly ICC, analyzed for DNA and RNA-seq and crossed with data obtained from
The Cancer Genome Atlas (TCGA) and other datasets—4 different clusters were identified on the
basis of the mutation and aberration profiles [12]. A particular subgroup of ICC resulted enriched for
IDH1 mutation (IDH1m) and is characterized by DNA hypermethylation, which influenced the gene
expression and the cell differentiation [13]. The prevalence of the codon 132 hotspot (R132x) IDH1m in
ICC is estimated to be 10–30% [14]. In a recent work, we analyzed the transcriptomic and mutational
profiles of paired primary and recurrent ICCs—we found that 5 out of 15 patients (33%) harbored
an IDH1 R132x mutation; of them, 4 displayed a naïve mutation only in the recurrent counterpart,
suggesting that IDH1m could be a marker of progression in ICC [15]. The prognostic role of IDH1m is
still controversial, with reports of better survival outcomes, of no association with survival at all [16–19],
and even of a detrimental effect on prognosis [20]. Due to its role as oncogene, the IDH1m has recently
become an attractive target for therapies, and some clinical trials are ongoing using specific IDH1m
inhibitors, in particular, in gliomas, hematologic malignancies and CCAs (NCT02074839; NCT02989857;
NCT03127735). Here, we evaluated the incidence of mutations in the exon 4 of IDH1, focusing on
the IDH1 R132x mutation, in an Italian series of 61 primary ICCs. We set up a quantitative real-time
allele-specific polymerase chain reaction (qPCR) assay to detect with high efficiency, comparable with
next generation sequencing (NGS) data [21], the specific IDH1m both in tissue and in plasma samples.
In particular, the reliability and sensitivity of the technique on tissues may extend the number of
patients in whom the IDH1m is detectable at an early stage and who can benefit from targeted therapy.
Moreover, the efficiency of the qPCR in plasma samples could provide a non-invasive tool to monitor
the progression of the disease. We also compared the sensitivity of qPCR with Sanger sequencing, the
conventional and cheapest method to detect gene mutations, frequently used in routine molecular
diagnostics, but characterized by lower sensitivity.
2. Results
2.1. Sensitivity of IDH1 R132x qPCR
We developed a qPCR assay able to identify the main IDH1R132x mutations (R132C, R132G,
R132H, R132L, R132S) in formalin-fixed paraffin-embedded (FFPE) samples and cfDNA.
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Standard curves were performed on mutated/wild-type (WT) positive controls (from 3 × 103 to
3 IDH1 copies) showing a mean efficiency (E) of 98.9%. Specific efficiency for each IDH1 mutation
and for the WT allele are summarized in Table 1. The efficiency is variable according to the
mutation analyzed.
Table 1. Mean threshold cycle (Ct) obtained with different concentration of plasmids for the IDH1R132x
mutations and wild-type (WT).
IDH1
Status
3000 Copies
(Ct)
300 Copies
(Ct)
30 Copies
(Ct)
3 Copies
(Ct) E R
2 Slope
WT 22.3 25.8 30.0 34.4 75.8 0.99 −4.1
R132C 27.3 30.6 34.0 37.1 98.9 0.99 −3.4
R132G 24.6 28.1 31.4 34.7 95.0 0.99 −3.5
R132H 28.2 30.8 33.1 35.8 133.6 0.99 −2.7
R132L 23.3 27.1 30.2 32.7 103.2 0.98 −3.3
R132S 22.6 26.4 29.7 32.6 102.9 0.99 −3.3
Ct: threshold cycle; E: efficiency; R2: coefficient of regression.
In order to simulate different percentages of mutated allele in the sample (from 8% to 2%; from
~2500 to 500 IDH1 gene copies), plasmids harboring the different IDH1 mutants were mixed with
IDH1 WT DNA—as shown in Table 2, qPCR is able to detect up to 2% of mutated allele, except for the
R132H mutant.
Table 2. Mean Ct obtained with different percentages of different IDH1R132x mutations inserted in
plasmid and IDH1 WT DNA.
IDH1
Mutation
8% Mutated Plasmid 4% Mutated Plasmid 2% Mutated Plasmid
M-FAM Ct WT-HEX Ct M-FAM Ct WT-HEX Ct M-FAM Ct WT-HEX Ct
R132C 26.0 28.9 26.9 28.6 27.9 28.5
R132G 27.0 28.9 27.8 28.5 28.9 28.5
R132H ND 28.9 ND 28.6 ND 28.3
R132L 28.5 28.3 33.1 28.2 37.0 28.7
R132S 27.0 28.9 27.3 28.5 28.4 28.4
M-FAM: mutated IDH1 labeled with FAM; WT-HEX: wild-type labeled HEX; ND: not detected.
Then, we tested the efficiency of the method in experiments in which DNA derived from three
patients with IDH1 mutations (two samples with R132L and one with R132G mutations, respectively)
was mixed with IDH1 WT DNA at different proportions (100%, 50%, 10%). In this case, we were able
to detect the mutations up to 10% diluted mutated samples (~5% mutated allele), but only in two out
of three samples, as shown in Table 3.
Table 3. Mean Ct obtained with IDH1 R132L and R132G mutated formalin-fixed paraffin-embedded
(FFPE) samples pooled with IDH1 WT DNA.
IDH1 Mutated Sample 50% 10%
ID Mutation M-FAM (Ct) WT-HEX (Ct) M-FAM (Ct) WT-HEX (Ct)
#11 R132L 29.2 29.1 36.7 28.8
#41 R132L 27.6 27.7 ND 28.4
#61 R132G 27.8 29.1 31.3 29.0
M-FAM: mutated IDH1 labeled with FAM; WT-HEX: wild-type labeled HEX; ND: not detected.
We also performed a DNA dilution experiment in which the R132G mutated sample was diluted
from 200 to 0.3 ng and we demonstrated that qPCR is able to detect up to 0.3 ng of mutated template,
as shown in Figure 1.
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Figure 1. Mean Ct obtained on diluted genomic DNA isolated from R132G mutated sample.
2.2. Comparison between Quantitative PCR (qPCR) and Nested PCR for the Identification of
IDH1R132x Mutations
A series of 61 ICC samples was analyzed to identify the frequency of IDH1 exon 4 mutations,
using both qPCR and nested PCR followed by Sanger sequencing.
By using qPCR with specific probes for each mutation (R132C/G/H/L/S), we detected 10 out of
61 mutated samples (16.4%). In particular, six patients displayed the R132L mutation (#11, #22, #41,
#46, #51 and #57), three patients the R132C mutation (#15, #21 and #45) and one patient (#61) the R132G
mutation. Ct values and amplification curves of qPCR of R132L and R132C/G mutated samples are
reported in Figures 2 and 3, respectively.
The same cohort was analyzed by nested PCR followed by Sanger sequencing. With this technique,
we were able to detect the mutations only in 5 out of 61 patients (8.2%); in particular, 4 patients
displayed the R132L (#11, #22, #41 and #51), as shown in Figure 4C, and one the R132G mutation (#61),
as shown in Figure 4B. The WT sequence is shown in Figure 4A.
Moreover, with Sanger sequencing we found also two novel, heterozygous point-missense
mutations within IDH1 exon 4, as shown in Figure 5; in particular, the mutation at codon 102 resulted
in the substitution of lysine with proline in patient #3, whereas the mutation at codon 56 resulted in
the substitution of threonine with isoleucine in patient #42.
Table 4 summarizes the mutations detected with the two techniques.
Cancers 2019, 11, 454 5 of 13
Cancers 2019, 11, x 5 of 16 
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Table 4. IDH1 hotspot mutations detected with the two techniques, respectively.
Patient ID Mutation Detected with Sanger Mutation Detected with qPCR
#11 R132L R132L
#15 R132C
#21 R312C
#22 R132L R132L
#41 R132L R132L
#45 R312C
#46 R132L
#51 R132L R132L
#57 R132L
#61 R132G R132G
2.3. cfIDH1m R132x is a Potential Prognostic Marker in ICC in Plasma Samples
For one patient, both the tumor biopsy and plasma samples (obtained at four different time points,
at the beginning of systemic treatment and every six weeks afterwards) were available. Both Sanger
sequencing and qPCR detected the IDH1m R132C in tissue biopsy. The liquid biopsy analysis for
this specific mutation performed on cfDNA revealed a progressive decrease of Ct, as it indicates an
increase of the mutated copies, from the first blood sampling to the latter, as shown in Figure 6A
and Figures S1–S3, suggesting that the mutated allele load is directly correlated with the disease
progression evaluated by CT scan, as shown in Figure 6B.Cancers 2019, 11, x 10 of 16 
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3. Discussion
In this work, we analyzed the incidence of IDH1 mutation in the hotspot codon 132 in an Italian
series of FFPE ICC samples and assessed two different techniques for detection of the mutation,
the allele specific qPCR, and the classical Sanger sequencing. We reported that 16.4% of patients
harbored one of the IDH1R132x mutations, similar to other studies [17,22–25]; however, only 5 out of
10 mutations were also detected also by Sanger sequencing (8.2%). We found that six samples carried
the R132L mutation, three samples the R132C and one the R132G; these mutations are already described
in ICC [25,26]. The absence of the R132H mutation, typical of glioblastoma, confirmed the already
reported data which described that ICCs have a different mutational pattern [27]. The difference in
sensitivity between the two techniques indicates that nested PCR followed by Sanger sequencing is
able to detect mutations only if the biological material is well preserved and probably if the mutated
clone is overrepresented; although this method is the cheapest one, data suggest that it is not efficient
to screen FFPE samples for mutations. We assessed the sensitivity of Sanger sequencing at 20 ng
(Figure S4); this data could also be influenced by scarce preservation of biological materials (i.e., DNA
fragmentation, formaldehyde-damaged DNA by formation of DNA-protein crosslinks, and DNA
breaks) which could impair the nested PCR due to longer primers compared to qPCR.
We performed different tests to assess the sensitivity of our qPCR assay; pooling plasmids
harboring the different IDH1 mutants with IDH1 WT DNA, we were able to detect at least 2% of
mutated allele, except for the R132H mutant. Starting from mutated DNA extracted from FFPE samples
and pooling with IDH1 WT DNA, we were able to detect up to 5% of mutated alleles. The seriate
dilutions of the R132G mutated sample revealed that qPCR could detect the mutation up to 0.3 ng of
DNA. The highest sensitivity of qPCR compared to Sanger qPCR is uncontested. A possible strategy to
improve our assay sensibility could be the use of a PNA clamp. This kind of probe is able to specifically
block WT allele amplification in favor of mutant allele, if present. We did not use a PNA-clamp for
our qPCR assay, because it was very important to avoid false negative results in plasma samples, due
to inadequate sampling. Further, the WT allele amplification in each qPCR was a positive control.
In recent years, other methods of mutation detection are frequently used, such as droplet PCR or
NGS. Both the techniques are regarded as more sensitive compared to qPCR allowing the detection
of less than 1% of mutated alleles, with the additional perk for NGS of multiple targets analyzed in
the same experiment. NGS is frequently used in screening procedures, in particular to select patients
with specific molecular alterations to be enrolled in clinical trials. However, the downside of such
a high sensitivity is that the identification of very low amounts of mutated clones could be useless
or even misleading from a clinical standpoint. Moreover, NGS is more prone to errors, due to the
complexity of the technical procedures and to the interpretation of the large amount of data. Further,
Gao and collaborators showed that NGS has certainly significant technical advantages, but qPCR
showed similar analytical sensitivity and specificity, as well as high concordance with data obtained
by NGS [21].
The innovation of our study is the capability of detecting the IDH1m in plasma samples, avoiding
false negative results due to the absence of IDH1 copies in tested samples. In this case report, we
were able to detect the mutation found in the FFPE sample also in cfDNA using the specific qPCR
probe; by longitudinally analyzing the seriate plasma samples, we revealed a progressive increase
of plasma concentration of IDH1m, which corresponded to the disease progression evidenced by
the clinical examinations. Literature is conflicting about the significance of IDH1m for the biological
aggressiveness and the course of the natural history of ICC. Hence, the prognostic role of IDH1m
remains controversial in ICC. Against this backdrop, in our recent work, the comparison of primary
and recurrent tumors revealed that in three cases the IDH1mR132x is detectable only in the recurrent
tumors, suggesting for IDH1m a possible role in ICC progression after surgery [15]. Data from the
present study add to these conclusions, supporting the hypothesis that plasma IDH1m could at least
represent a biomarker of progression of advanced disease. The main limit of our study was that we
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tested the sensitivity of our qPCR assay analysis only in one patient, as a case report: further studies
will be needed to validate our findings with a more conspicuous case series.
4. Materials and Methods
4.1. Patients
A retrospective series of 61 formalin-fixed, paraffin embedded (FFPE) samples, obtained from
ICC patients diagnosed between 2005 and 2013, was collected from two Italian centers, the Institute
of Candiolo and the Humanitas Clinical and Research Center of Rozzano. The Institute Review
Board Ethical Committees of both centers approved the use of archival tissues for this specific
research (Institute of Candiolo: 17 October 2018, ethic code 298/2018; Humanitas Clinical and
Research Center: 18 October 2016, ethic code 1270). Three-micron thick slides were used for DNA
extraction for each tumor. Tumor areas were identified by a pathologist by hematoxylin/eosin
staining. Blood samples were collected from a single ICC patient, treated at our institute from May to
September 2018. The patient was a 61 year old woman initially diagnosed with a stage IIIB, poorly
differentiated (G3), multifocal cholangiocarcinoma, who had undergone a surgical intervention of
right hepatectomy with locoregional lymphadenectomy. Upon disease recurrence, she was treated
with three chemotherapy lines. At the time of disease recurrence, an assessment of somatic mutations
was performed that revealed an IDH1 R132C mutation. To test the efficiency of qPCR on plasma,
blood samples were collected according to the Institute Review Board Ethical Committee. The patient
signed the informed consent of PROFILING protocol (“Prospective study for the determination of
molecular profiles of patients affected by tumors resistant to target therapies.”) Studio prospettico
per la determinazione del profilo molecolare di resistenza alle terapie target in pazienti con malattie
neoplastiche”, 001-IRCC-00IIS-10, version 6.1, FPO-IRCCS, l’Istituto di Ricovero e Cura a Carattere
Scientifico Candiolo (TO), 23 June 2016).
Blood draws were performed at four time points—at the beginning of treatment for metastatic
disease and then every 6 weeks during treatment, until disease progression, which occurred after
18 weeks of treatment.
4.2. DNA Extraction from FFPE Tissues
Genomic DNA was extracted using QIAamp DNA FFPE Mini kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Briefly, tumor tissues were scraped and collected in 2 mL
tubes. Tissues were then rehydrated by subsequent passages in xylene and ethanol; pellets were then
treated and lyzed with proteinase K and lysis buffer over night at 56 ◦C. DNA purification and elution
were performed using a column. DNA was quantified using the spectrophotometer Nanodrop 2000c
(Thermo Fisher Scientific, Waltham, MA, USA).
4.3. DNA Isolation from Plasma Samples
For the liquid biopsy test, we started from plasma isolated from blood samples. Briefly, three
EDTA tubes were centrifuged at 3000 rpm for 10 min at room temperature without brake, then
supernatant was transferred in 15 mL polystyrene tubes and a second centrifugation was performed
at 4000 rpm for 10 min at room temperature with brake. Plasma was then divided in aliquots and
preserved at −80 ◦C. Cell free (cf) DNA was isolated using the MagMAX Cell-Free DNA Isolation Kit
(Applied Biosystems, Foster City, CA, USA), following the manufacturer instructions. Lysis solution
was mixed with 2 mL of plasma and incubated in agitation with cfDNA magnetic beads for 10 min.
Beads were washed once with wash solution and twice with 80% ethanol. cfDNA was eluted with
35 µL of elution solution. Samples were stored at 4 ◦C until testing. All the cfDNA collected was
subdivided into the test wells.
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4.4. IDH1 Mutational Analysis
In order to analyze the mutational status of the hotspot codon 132 in the exon 4 of IDH1 we used
two different methods, the quantitative real-time allele-specific polymerase chain reaction (qPCR)
system and the nested PCR followed by Sanger sequencing. The relative primers of each technique are
indicated in Table S1.
The qPCR assay was performed on CFX96 (Bio-Rad, Hercules, CA, USA) using Takyon No
Rox probe 5× MasterMix dTTP (Eurogentec SA, Seraing, Belgium). DNA samples isolated from
FFPE tissues and plasma were amplified specific using primers, as shown in Table S1, flanking
codon 132 (88 bp) at the final concentration of 200 nM. Probes were modified with locked nucleic
acid (LNA) bases to enhance the assay specificity. Specific LNA-modified probes were synthesized
for each mutation (R132C, R132L, R132G, R132H and R132S; FAM labeled) and wild-type allele
(HEX labeled) (Eurogentec). In each reaction, the specific mutation and WT probes were mixed at
different concentrations (final concentration 100 nM) as shown in Table S1.
As a positive control, a construct of 201 bp containing the sequence of IDH1 exon 4 with the
specific variation was inserted in a pUC57 plasmid (Eurogentec). Human female DNA reference
(Agilent Technologies, Santa Clara, CA, USA) was used to test the WT probe.
Plasmids, probes and primers were quantified using a DS33 nano spectrophotometer (Denovix
Inc., Wilmington, DE, USA) and Qubit dsDNA HS assay (Qiagen).
In order to test the assay sensitivity, plasmids and human DNA reference were diluted to build
a four-point standard curve. Each specific plasmid (starting from 3 × 103 to 3 copies) was tested in
duplicate to increase the accuracy of the test.
The sensitivity of IDH1 qPCR assay was analyzed in three different experiments: (1) pooling
3 × 103 copies of WT IDH1 DNA with different concentrations of plasmid harboring IDH1 mutation
(range 2–8%); (2) mixing DNA derived from 3 IDH1 mutated samples (1 R132G; 2 R132L) with DNA
from an IDH1 wild-type sample (pure, 50% mutated and 10% mutated; 10 ng of total DNA); (3) diluting
(1:10 for the first dilution, then 1:2) DNA derived from an R132G sample (from 200 to 0.3 ng).
Nested PCR was used to evaluate the mutational status of the hotspot codon 132 in the exon 4
of IDH1. The external and internal primers are indicated in Table S1. For the first round of PCR, the
conditions were: 95 ◦C 5 min, 95 ◦C 30 s, 55 ◦C 30 s, 72 ◦C 45 s, repeated for 40 cycles with a final
extension period of 72 ◦C 7 min. For the second round, a touch down PCR was used. PCR products
(360 bp) were then purified using Wizard® SV Gel and a PCR Clean-Up System (Promega, Italy) and
sense and antisense sequences were obtained using forward and reverse internal primers, respectively.
Each exon was sequenced using the BigDye Terminator Cycle sequence following the PE Applied
Biosystem strategy and Applied Biosystem ABI PRISM3100 DNA Sequencer (Applied Biosystem).
Mutations were confirmed performing two independent rounds of PCR amplifications and sequencing.
4.5. Analysis of IDH1 PCR Data
In order to evaluate the performance of each primer set, a standard curve was designed. A seriate
dilution of the target (10-fold dilution for 4 log) was analyzed. We tested 5 plasmids each with
a specific IDH1 mutation and a genomic DNA as IDH1 WT reference. Ct (threshold cycle) is the
intersection between an amplification curve and a threshold line. It is a relative measure of the
concentration of target in the PCR reaction. R2 is the coefficient of correlation obtained for the standard
curve; its value should be >0.99 to consider the correlation as significant. Ideally, the efficiency
(E) of a PCR should be around 100%, meaning that for each cycle the amount of product doubles.
This efficiency is calculated from the slope(s) of the standard curves according to the following formula:
E = (10(−1/slope) − 1) × 100. For an efficiency of 100%, the slope is −3.32. A good reaction should have
an efficiency between 90% and 110%, which corresponds to a slope between −3.58 and −3.10.
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5. Conclusions
In conclusion, our qPCR assay may represent a useful, rapid and cheap tool to identify IDH1
mutations in FFPE samples or to validate data obtained by high-throughput techniques. Of interest,
this qPCR is able to detect the IDH1 mutations also in plasma samples in cfDNA samples, avoiding
false negative results. Hence, qPCR could reveal a suitable, non-invasive assay to integrate the standard
clinical, radiologic and biohumoral restaging assessment in the course monitoring of IDH1m ICC.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/4/454/s1,
Figure S1: Ct values and amplification curves of qPCR of cfDNA obtained from 1 IDH1m patient analyzed at
different time points. In blue the WT curves, in green the mutated ones, Figure S2: CT scan images at the baseline
(A) and after 6 weeks (B). Scale bar represent 10 mm, Figure S3: CT scan images at 12 weeks (C) and 18 weeks (D)
from baseline. Scale bar represent 10 mm, Figure S4: Sensitivity of nested PCR for the amplification of IDH1 exon
4, Table S1: Primers used for IDH1 mutational analysis. Probes and oligonucleotides for qPCR.
Author Contributions: C.P.-N. conceived the study, performed the experiments and wrote the first article draft;
M.S. conceived the study and wrote the final article draft; E.G. performed the qPCR experiments; P.L., R.F., C.R.
and C.M. collected tumor samples and revised the article draft; G.C., M.A. and F.L. conceived the study and
revised the article draft.
Funding: Part of the project, in particular qPCR assay set up, was funded by Fondazione Edo ed Elvo Tempia.
Acknowledgments: Fondazione Piemontese per la Ricerca sul Cancro-Onlus (FPRC) 5X1000—“Identification of
new druggable pathways in intrahepatic cholangiocarcinoma”; Ministero della Salute 2010; Fondo per la ricerca
locale (Linea B), LEOF_RIC_LOC_14_01 project title: “Transcriptomic and genetic analysis of paired primary and
recurrent intrahepatic cholangiocarcinoma”; Progetto di Rete–NET-2011-02352137 “Genomic base triage for target
therapy in colorectal cancer” Ricerca Sanitaria Finalizzata 2011.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Alvaro, D.; Crocetti, E.; Ferretti, S.; Bragazzi, M.C.; Capocaccia, R.; The AISF “Cholangiocarcinoma”
Committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig. Liver Dis. 2010, 42, 490–495.
[CrossRef] [PubMed]
2. Cho, K.M.; Park, H.; Oh, D.Y.; Kim, T.Y.; Lee, K.H.; Han, S.W.; Im, S.A.; Bang, Y.J. Neutrophil-to-lymphocyte
ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a
more accurate prognosis of advanced biliary tract cancer. Oncotarget 2017, 8, 2329–2341. [CrossRef] [PubMed]
3. Rizvi, S.; Gores, G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013,
145, 1215–1229. [CrossRef]
4. de Jong, M.C.; Hong, S.M.; Augustine, M.M.; Goggins, M.G.; Wolfgang, C.L.; Hirose, K.; Schulick, R.D.;
Choti, M.A.; Anders, R.A.; Pawlik, T.M. Hilar cholangiocarcinoma: Tumor depth as a predictor of outcome.
Arch. Surg. 2011, 146, 697–703. [CrossRef] [PubMed]
5. Ni, Q.; Shen, W.; Zhang, M.; Yang, C.; Cai, W.; Wu, M.; Yang, J. Prognostic analysis of radical resection for
intrahepatic cholangiocarcinoma: A retrospective cohort study. Oncotarget 2017, 8, 75627–75637. [CrossRef]
[PubMed]
6. Jain, A.; Javle, M. Molecular profiling of biliary tract cancer: A target rich disease. J. Gastrointest. Oncol. 2016,
7, 797–803. [CrossRef] [PubMed]
7. Lee, H.; Ross, J.S. The potential role of comprehensive genomic profiling to guide targeted therapy for
patients with biliary cancer. Ther. Adv. Gastroenterol. 2017, 10, 507–520. [CrossRef] [PubMed]
8. Ong, C.K.; Subimerb, C.; Pairojkul, C.; Wongkham, S.; Cutcutache, I.; Yu, W.; McPherson, J.R.; Allen, G.E.;
Ng, C.C.; Wong, B.H.; et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet.
2012, 44, 690–693. [CrossRef] [PubMed]
9. Sia, D.; Tovar, V.; Moeini, A.; Llovet, J.M. Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for
molecular therapies. Oncogene 2013, 32, 4861–4870. [CrossRef] [PubMed]
10. Peraldo Neia, C.; Cavalloni, G.; Balsamo, A.; Venesio, T.; Napoli, F.; Sassi, F.; Martin, V.; Frattini, M.;
Aglietta, M.; Leone, F. Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.
Genes Chromosomes Cancer 2014, 53, 1033–1040. [CrossRef] [PubMed]
Cancers 2019, 11, 454 13 of 13
11. Lombardi, P.; Marino, D.; Fenocchio, E.; Chilà, G.; Aglietta, M.; Leone, F. Emerging molecular target
antagonists for the treatment of biliary tract cancer. Expert. Opin. Emerg. Drugs 2018, 23, 63–75. [CrossRef]
12. Farshidfar, F.; Zheng, S.; Gingras, M.C.; Newton, Y.; Shih, J.; Robertson, A.G.; Hinoue, T.; Hoadley, K.A.;
Gibb, E.A.; Roszik, J.; et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct
IDH-Mutant Molecular Profiles. Cell Rep. 2017, 19, 2878–2880. [CrossRef] [PubMed]
13. Raineri, S.; Mellor, J. Linking Metabolism and Epigenetics. Front. Genet. 2018, 9, 493. [CrossRef]
14. Grassian, A.R.; Pagliarini, R.; Chiang, D.Y. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic
cholangiocarcinoma. Curr. Opin. Gastroenterol. 2014, 30, 295–302. [CrossRef]
15. Peraldo-Neia, C.; Ostano, P.; Cavalloni, G.; Pignochino, Y.; Sangiolo, D.; De Cecco, L.; Marchesi, E.;
Ribero, D.; Scarpa, A.; De Rose, A.M.; et al. Transcriptomic analysis and mutational status of IDH1 in
paired primary-recurrent intrahepatic cholangiocarcinoma. BMC Genom. 2018, 19, 440. [CrossRef]
16. Cercek, A.; Kemeny, N.E.; Boerner, T.; Tan, B.R.; Chou, J.F.; Gonen, M.; Boucher, T.M.; Hauser, H.;
Do Richard, K.G.; Lowery, M.A.; et al. A bi-institutional phase II study of hepatic arterial infusion (HAI)
with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin
(GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC). J. Clin. Oncol. 2018, 36, 4092. [CrossRef]
17. Wang, P.; Dong, Q.; Zhang, C.; Kuan, P.F.; Liu, Y.; Jeck, W.R.; Andersen, J.B.; Jiang, W.; Savich, G.L.; Tan, T.X.;
et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas
and share hypermethylation targets with glioblastomas. Oncogene 2013, 32, 3091–3100. [CrossRef]
18. Jusakul, A.; Cutcutache, I.; Yong, C.H.; Lim, J.Q.; Huang, M.N.; Padmanabhan, N.; Nellore, V.; Kongpetch, S.;
Ng, A.W.T.; Ng, L.M.; et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes
of Cholangiocarcinoma. Cancer Discov. 2017, 7, 1116–1135. [CrossRef] [PubMed]
19. Goyal, L.; Govindan, A.; Sheth, R.A.; Nardi, V.; Blaszkowsky, L.S.; Faris, J.E.; Clark, J.W.; Ryan, D.P.;
Kwak, E.L.; Allen, J.N.; et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage
Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist
2015, 20, 1019–1027. [CrossRef]
20. Jiao, Y.; Pawlik, T.M.; Anders, R.A.; Selaru, F.M.; Streppel, M.M.; Lucas, D.J.; Niknafs, N.; Guthrie, V.B.;
Maitra, A.; Argani, P.; et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A
and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 2013, 45, 1470–1473. [CrossRef]
21. Gao, J.; Wu, H.; Shi, X.; Huo, Z.; Zhang, J.; Liang, Z. Comparison of Next-Generation Sequencing, Quantitative
PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung
Tumors. Clin. Lab. 2016, 62, 689–696. [CrossRef] [PubMed]
22. Moeini, A.; Sia, D.; Bardeesy, N.; Mazzaferro, V.; Llovet, J.M. Molecular Pathogenesis and Targeted Therapies
for Intrahepatic Cholangiocarcinoma. Clin. Cancer Res. 2016, 22, 291–300. [CrossRef] [PubMed]
23. Kipp, B.R.; Voss, J.S.; Kerr, S.E.; Barr Fritcher, E.G.; Graham, R.P.; Zhang, L.; Highsmith, W.E.; Zhang, J.;
Roberts, L.R.; Gores, G.J.; et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Hum. Pathol. 2012, 43, 1552–1558. [CrossRef]
24. Lowery, M.A.; Ptashkin, R.; Jordan, E.; Berger, M.F.; Zehir, A.; Capanu, M.; Kemeny, N.E.; O’Reilly, E.M.;
El-Dika, I.; Jarnagin, W.R.; et al. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic
Cholangiocarcinomas: Potential Targets for Intervention. Clin. Cancer Res. 2018, 24, 4154–4161. [CrossRef]
[PubMed]
25. Borger, D.R.; Tanabe, K.K.; Fan, K.C.; Lopez, H.U.; Fantin, V.R.; Straley, K.S.; Schenkein, D.P.; Hezel, A.F.;
Ancukiewicz, M.; Liebman, H.M.; et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in
cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012, 17, 72–79. [CrossRef]
26. Saha, S.K.; Parachoniak, C.A.; Bardeesy, N. IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle
2014, 13, 3176–3182. [CrossRef] [PubMed]
27. Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.;
Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. Cell
2013, 155, 462–477. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
